dcsimg Aranesp® (darbepoetin alfa) – Dosing Information
› Email› Print

Dosing information for Aranesp® (darbepoetin alfa) for anemia due to CKD

Important Safety Information

  • Serious allergic reactions, including anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria may occur with Aranesp®. Immediately and permanently discontinue Aranesp® if a serious allergic reaction occurs.
  • Adverse reactions (≥ 10%) in Aranesp® clinical studies in patients with CKD were hypertension, dyspnea, peripheral edema, cough, and procedural hypotension.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
CKD = chronic kidney disease; ESA = erythropoiesis-stimulating agent; Hb = hemoglobin; IV = intravenous; QW = once weekly; Q2W = once every 2 weeks; Q4W = once every 4 weeks; RBC = red blood cell; SC = subcutaneous.

Biotechnology by Amgen®